T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, et al. Nat Med 2024;30:984-989.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med 2024;30:984-989.
PMID: 38266761